Eli Lilly nears deal to buy psychedelic drugmaker AtaiBeckley, Bloomberg News reports

Merger Arbeconomics, downside, days

Deal value

—

Per-share offer

—

Premium

—

Days to close

—

Term fee

—

Consideration—

AnnouncedJul 16, 2026

Days outstanding48d

Expected close—

Termination fee—

Reverse term fee—

Go-shop period—

Fiduciary out—

Financing condition—

Debt commitment—

Insider lock-up—

No structured deal economics extracted yet. Re-run the scanner or fall back to the source filing below.

Timelineannounced → close

Announced
Jul 16, 2026
Preliminary Proxy
—
Definitive Proxy
—
Record date
—
Shareholder vote
—
Expected close
—

Vote Mechanicsrecord / mailing / vote

Vote date—

Record date—

Mailing date—

Record → vote—

Threshold—

Min approvalparsed—

Shares outstanding—

Insider lock-up—

Regulatory & ConditionsHSR / EU / CFIUS / MAC

No regulatory or closing-conditions data extracted yet. The merger agreement Exhibit 10.1 contains this in the “Conditions to Closing” and “Regulatory Approvals” articles.

Closing Conditionsapprovals · vote · financing · lockups

No closing-condition data extracted.

Interloper Riskcompeting bids, activist filers

No competing-bidder, activist, or dissident-proxy signals in the database for this target.

Advisors

No advisor data on record for this deal.

Sources

Press Release

Eli Lilly is in talks to acquire psychedelic drugmaker ‌AtaiBeckley and a deal could be announced as soon as this week, Bloomberg News reported on...

Item id: 34817250-16ee-4421-b5e1-4f63119f56c3 · ingested Jul 16, 2026